DRKS00031004招募中2 期
A Randomized Controlled Trial of Positive Psychology and Stress Management Interventions for Test Anxiety and Test-Related Stress
niversität Konstanz0 个研究点目标入组 210 人开始时间: 2023年2月16日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 210
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 40 Years（—）
- 性别
- All
入选标准
- •Students who have at least two written exams remaining.
排除标准
- •Severe depressive episodes, suicidality, participants currently undergoing psychotherapeutic treatment, participants taking medication.
研究者
相似试验
进行中（未招募）
1 期
A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 TreatmentMedDRA version: 20.0Level: LLTClassification code 10001624Term: Alcoholic hepatitisSystem Organ Class: 100000004871Alcoholic hepatitisEUCTR2020-004534-38-DEDURECT Corporation300
进行中（未招募）
1 期
OMS721 in patients with IgA Nephropathy (ARTEMIS-IGAN)IgA nephropathy (IgAN)EUCTR2018-000075-33-ESOmeros Corporation434
进行中（未招募）
不适用
A study of AMG 416 in the treatment of secondary hyperparathyroidism in chronic kidney diseaseEUCTR2012-002806-31-HUKAI Pharmaceuticals, Inc. (a subsidiary of Amgen, Inc.)500
进行中（未招募）
1 期
A Randomized, Double-blind, Placebo-controlled, Phase 2 Clinical Trial of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)EUCTR2013-003713-18-ITMillennium Pharmaceuticals, Inc178
进行中（未招募）
不适用
A study of AMG 416 in the treatment of secondary hyperparathyroidism in chronic kidney diseaseSecondary hyperparathyroidism in subjects with chronic kidney diseaseMedDRA version: 17.0Level: PTClassification code 10020708Term: Hyperparathyroidism secondarySystem Organ Class: 10014698 - Endocrine disordersMedDRA version: 17.0Level: LLTClassification code 10020706Term: Hyperparathyroidism NOSSystem Organ Class: 10014698 - Endocrine disordersEUCTR2012-002805-23-ATKAI Pharmaceuticals, Inc (a subsidiary of Amgen, Inc.)500